Further translational research is needed to optimize ways of inhibiting EGFR using single-agent or combination regimens and to identify patients who benefit the most from these therapies.

• 使用单药或联合用药阻断EGFR(表皮生长因子受体)的各种方法的可行性；以及哪些人群能从这些治疗方法中获得最大收益；需要对翻译过程的进一步研究.